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Mitochondrial reactive oxygen 
species generation in blood cells 
is associated with disease severity 
and exercise intolerance in heart 
failure patients
Ryosuke Shirakawa1, takashi Yokota  1, takayuki nakajima1, Shingo takada1, 
Miwako Yamane1, takaaki furihata1, Satoshi Maekawa1, Hideo nambu1, takashi Katayama1, 
Arata fukushima1, Akimichi Saito1, naoki ishimori1, flemming Dela2,3, Shintaro Kinugawa  1 
& toshihisa Anzai1
Systemic oxidative stress plays a key role in the development of chronic heart failure (cHf). We tested 
the hypothesis that mitochondrial reactive oxygen species (RoS) generation in circulating peripheral 
blood mononuclear cells (PBMCs) contributes to CHF progression. A total of 31 patients who had a 
history of hospital admission due to worsening Hf were enrolled and grouped as having either mild cHf 
defined as New York Heart Association (NYHA) functional class I-II or moderate-to-severe CHF defined 
as NYHA functional class III. ROS levels in PBMC mitochondria were significantly increased in CHF 
patients with NYHA functional class III compared to those with NYHA functional class I-II, accompanied 
by impaired mitochondrial respiratory capacity in pBMcs. RoS generation in pBMc mitochondria 
was positively correlated with urinary 8-hydroxydeoxyguanosine, a systemic oxidative stress marker, 
in cHf patients. importantly, mitochondrial RoS generation in pBMcs was directly correlated with 
plasma levels of B-type natriuretic peptide, a biomarker for severity of HF, and inversely correlated with 
peak oxygen uptake, a parameter of exercise capacity, in cHf patients. the study showed that RoS 
generation in pBMc mitochondria was higher in patients with advanced cHf, and it was associated with 
disease severity and exercise intolerance in cHf patients.
Chronic heart failure (CHF) is a progressive clinical syndrome characterized by systemic illness such as ane-
mia, renal failure, vascular endothelial dysfunction, and skeletal muscle dysfunction as well as cardiac dysfunc-
tion after initial onset of acute heart failure1–4. In particular, exercise intolerance is a cardinal symptom of CHF, 
and reflects a poor systemic physical condition leading to worse clinical outcomes5. Growing evidence suggests 
that systemic oxidative stress plays a key role in the development of CHF and can be used as an indirect and 
non-specific marker to predict disease severity and prognosis in these patients6–8. However, the underlying mech-
anism of enhanced systemic oxidative stress, including the origin of reactive oxygen species (ROS) in advanced 
CHF, remains fully unknown.
It has been shown that mitochondrial dysfunction is involved in CHF9–11. Mitochondria are a major source of 
ROS, and ROS-damaged mitochondria generate more ROS, in a self-reinforcing process known as “ROS-induced 
ROS generation”11. It was previously shown that CHF patients had a higher proportion of mitochondrial 
ROS-loaded white blood cells12. Among white blood cells, peripheral blood mononuclear cells (PBMCs), i.e., 
lymphocytes and monocytes, rely on mitochondrial oxidative metabolism, while neutrophils do not13. Previous 
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studies have shown that mitochondrial dysfunction in PBMCs is related to the pathogenesis or development of 
a wide variety of chronic diseases, such as autism, depression, and amyotrophic lateral sclerosis14–16. In addition, 
a recent report demonstrated that mitochondrial respiratory capacity in PBMCs was depressed in patients with 
early-stage CHF (asymptomatic patients)17, but the role of PBMC mitochondrial dysfunction in the development 
of CHF remains unclear.
Here we focused on mitochondrial dysfunction in PBMCs, which have a higher demand for oxidative metab-
olism, and hypothesized that increased levels of mitochondrial ROS in circulating PBMCs might contribute to 
the development of CHF. The aims of this study were to compare the mitochondrial ROS generation in circulat-
ing PBMCs in patients with mild CHF defined as New York Heart Association (NYHA) functional class I-II or 
moderate-to-severe CHF defined as NYHA functional class III, and to investigate its association with disease 
severity and exercise intolerance in CHF patients.
Results
Baseline characteristics. Baseline data of the CHF population are presented according to NYHA func-
tional class in Table 1. There was no significant difference in age, gender, body weight, body mass index, cardio-
vascular risk factors, primary cause of HF, or medications between the NYHA I-II and NYHA III groups. There 
was no significant difference in urinary 8-hydroxydeoxyguanosine (8-OHdG), a systemic oxidative stress marker, 
between these groups. The plasma level of B-type natriuretic peptide (BNP), an established biomarker of HF 
severity, was significantly higher in the NYHA III group than the NYHA I-II group. The left ventricular ejection 
fraction (LVEF), a parameter of left ventricular systolic function, was significantly lower in the NYHA III group. 
In addition, the NYHA III group had a reduced peak oxygen uptake (VO2) compared to the NYHA I-II group, 
suggesting exercise intolerance.
Mitochondrial respiratory capacity and RoS generation in pBMcs. The NYHA III group had 
a lower mitochondrial respiratory capacity during state 3 respiration with complex I + II-linked substrates 
(CI + II_P) in PBMCs (Fig. 1A). In addition, the maximal electron transfer system (ETS) capacities with complex 
I + II-linked substrates (CI + II_E) and with complex II-linked substrates (CII_E) in PBMCs, respectively, were 
significantly reduced in the NYHA III group compared to the NYHA I-II group (Fig. 1A). Importantly, CHF 
patients with NYHA functional class III disease had higher mitochondrial ROS generation during state 3 respi-
ration with complex I + II-linked substrates (CI + II_P) in their PBMCs compared to CHF patients with NYHA 
functional class I-II (Fig. 1B). Similarly, mitochondrial ROS generation in PBMCs was higher after addition of 
NYHA I-II 
(n = 15)
NYHA III 
(n = 16) P-value
Age, years 63 ± 13 61 ± 14 0.637
Male 14 (93) 15 (94) 0.962
Body weight, kg 66.6 ± 11.1 66.9 ± 14.7 0.948
Body mass index, kg/m2 24.4 ± 3.5 24.1 ± 4.5 0.837
Primary cause of heart failure
Ischemic 4 (27) 7 (44) 0.321
Non-ischemic 11 (73) 9 (56) 0.321
Cardiovascular risk factors
Hypertension 5 (33) 1 (6) 0.057
Diabetes mellitus 4 (27) 7 (44) 0.321
Dyslipidemia 6 (40) 10 (63) 0.210
Urinary 8-OHdG, ng/
mg Cr 9.3 ± 2.8 11.5 ± 6.1 0.198
Plasma BNP, pg/dL 101.8 ± 105.0 286.2 ± 240.7 0.011
LVEF, % 44.3 ± 14.5 26.9 ± 6.0 <0.001
Peak VO2, mL/kg/min 19.5 ± 4.6 14.5 ± 4.3 0.003
Medications
β-blockers 14 (93) 16 (100) 0.294
ACEI/ARB 12 (80) 16 (100) 0.060
Aldosterone antagonists 9 (60) 12 (75) 0.372
Statins 6 (40) 11 (69) 0.108
Metformin 0 (0) 1 (6) N.A.
DPP4 inhibitors 0 (0) 3 (19) N.A.
SGLT2 inhibitors 0 (0) 2 (13) N.A.
Table 1. Demographic and clinical characteristics of CHF patients with NYHA functional class I-II and NYHA 
functional class III. Values are means ± SDs or n (%). ACEI, angiotensin-converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; BNP, B-type natriuretic peptide; 8-OHdG, 8-hydroxydeoxyguanosine; DPP4, 
dipeptidyl peptidase 4; LVEF, left ventricular ejection fraction; N.A., not applicable; NYHA, New York Heart 
Association; SGLT2, sodium-glucose transport protein 2; VO2, oxygen uptake.
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carbonylcyanide p-trifluoromethoxyphenylhydrazone (FCCP) with complex I + II-linked substrates (CI + II_E) 
and with complex II-linked substrates (CII_E) in the NYHA functional class III patients (Fig. 1B).
Associations between mitochondrial RoS generation in pBMcs and systemic oxidative 
stress. Mitochondrial ROS generation in PBMCs during all respiratory states was positively correlated with 
urinary 8-OHdG, a biomarker of oxidative DNA damage, in CHF patients (Fig. 2), which suggested that the 
increased levels of mitochondrial ROS in PBMCs were associated with systemic oxidative stress in CHF patients.
Associations between mitochondrial RoS generation in pBMcs and severity of heart fail-
ure. Mitochondrial ROS generation during all states in PBMCs was positively correlated with plasma BNP lev-
els (Fig. 3A–E), but there was no significant correlation between urinary 8-OHdG and plasma BNP levels in CHF 
patients (Fig. 3F). These results indicated that PBMC mitochondrial ROS generation—but not the non-specific 
biomarker of systemic oxidative damage—was related to severity of HF.
Associations between mitochondrial RoS generation in pBMcs and exercise capacity. ROS 
generation in PBMC mitochondria during all states was inversely correlated with peak VO2 (Fig. 4A–E), suggest-
ing that mitochondrial ROS levels in PBMCs were associated with exercise intolerance in CHF patients. However, 
urinary 8-OHdG was not significantly correlated with peak VO2 (Fig. 4F) in CHF patients.
Discussion
To the best of our knowledge, this is the first study to demonstrate that mitochondrial ROS generation in circu-
lating PBMCs is markedly increased in patients with moderate-to-severe (symptomatic) CHF compared to that 
in patients with mild (almost asymptomatic) CHF as defined by NYHA functional class. Notably, the increased 
levels of mitochondrial ROS in PBMCs, but not urinary OHdG, were associated with disease severity (i.e., higher 
plasma BNP level) and exercise intolerance (i.e., lowered peak VO2) in CHF patients.
It has been shown that elevation of myocardial ROS generation causes contractile failure and structural dam-
age, thereby leading to myocardial dysfunction in the failing heart18–20. In clinical settings, however, CHF is char-
acterized by systemic illness such as endothelial dysfunction, skeletal muscle changes, and renal impairment, and 
systemic oxidative stress plays a crucial role in the development of CHF21. In this study, ROS generation in PBMC 
mitochondria was increased in CHF patients with NYHA functional class III compared to those with NYHA 
functional class I-II, and it had a weak but positive correlation with urinary 8-OHdG in CHF patients, suggesting 
that PBMC-derived mitochondrial ROS may be a source of systemic oxidative stress in CHF.
Unexpectedly, urinary 8-OHdG was not higher in CHF patients with NYHA functional class III compared 
to those with NYHA functional class I-II, which is inconsistent with a previous study7. However, another report 
found that urinary 8-OHdG levels were not higher in CHF patients of NYHA functional class III-IV taken from 
a non-ischemic population22. In our study, the percentages of non-ischemic patients in the NYHA I-II group 
and the NYHA III group were 73% and 56%, respectively, and these values seem to be higher than those for the 
general CHF population. The inclusion of a larger non-ischemic population could have influenced the results of 
urinary 8-OHdG in CHF patients in this study.
In this study, mitochondrial ROS generation during state 3 respiration with complex I + II-linked substrates, 
but not that with complex I-linked substrates, in PBMCs were increased in CHF patients with NYHA functional 
class III compared to those with NYHA functional class I-II. Among mitochondrial ETS complexes, complexes I 
and III are generally regarded as the main sources of ROS, but complex II has recently drawn much attention as an 
Figure 1. Mitochondrial respiratory capacity and mitochondrial ROS generation in PBMCs of CHF patients. 
(A) Mitochondrial respiratory capacity during each state in PBMCs in the NYHA I-II group (n = 15) and the 
NYHA III group (n = 16). (B) Mitochondrial ROS generation during each state in PBMCs in the NYHA I-II 
group (n = 15) and the NYHA III group (n = 16). Bar: means ± SDs. *P < 0.05. CI, complex I-linked substrates; 
CI + II, complex I + II-linked substrates; CII, complex II-linked substrates; E, maximal capacity of electron 
transfer system; H2O2, hydrogen peroxide; L, leak-state (non-ADP stimulated state); P, state 3 (ADP-stimulated 
state).
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Figure 2. Association of systemic oxidative stress with mitochondrial ROS generation in PBMCs in CHF 
patients. Blue and red circles indicate CHF patients with NYHA functional class I-II (n = 15) and those with 
NYHA functional class III (n = 16), respectively. 8-OHdG, 8-hydroxydeoxyguanosine. Other abbreviations are 
as defined in the legend to Fig. 1.
Figure 3. Association of plasma BNP level with mitochondrial ROS generation in PBMCs or with systemic 
oxidative stress in CHF patients. Associations of the plasma BNP level with mitochondrial ROS generation 
during each respiratory state (A–E) and of the plasma BNP level with systemic oxidative stress (F). Blue and red 
circles indicate CHF patients with NYHA functional class I-II (n = 15) and those with NYHA functional class 
III (n = 16), respectively. BNP, B-type natriuretic peptide. Other abbreviations are as defined in the legend to 
Fig. 1.
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important source of ROS23. Indeed, the flavin site in complex II is reported to be a major contributor to mitochon-
drial ROS generation under physiological conditions24. Taken together, these findings suggest that complex II 
may play a role in the increased ROS generation in PBMC mitochondria in patients with advanced CHF, although 
we did not directly measure complex II-derived mitochondrial ROS generation in this study.
Plasma BNP is a well-established biomarker of HF that predicts clinical outcomes, including mortality and 
morbidity, in CHF patients25. We found that mitochondrial ROS generation in PBMCs, but not urinary 8-OHdG, 
was linked to plasma BNP levels in CHF patients, suggesting that mitochondrial ROS generation in circulating 
PBMCs may directly reflect the disease severity of HF rather than urinary 8-OHdG, a non-specific biomarker of 
oxidative damage.
CHF is a syndrome characterized by exercise intolerance with symptoms of exercise-induced dyspnea or 
fatigue. Indeed, exercise capacity is an independent predictor of all-cause death in CHF patients26. Here we 
showed that there was an association between increased mitochondrial ROS generation in PBMCs and lowered 
peak VO2 in CHF patients. Because determinants of VO2 are multifactorial, including cardiac function, pulmo-
nary circulation, peripheral blood flow, and skeletal muscle dysfunction, a variety of abnormalities may contrib-
ute to the lowered peak VO2 in CHF patients. A previous study revealed that blood cell mitochondrial respiratory 
capacity reflects cardiac and skeletal muscle energy metabolism27. In the present study, we showed that increased 
generation of mitochondrial ROS coexisted with impaired mitochondrial respiratory capacity in PBMCs; there-
fore, ROS levels in PBMC mitochondria might also be linked to mitochondrial dysfunction in cardiac and/or 
skeletal muscles in CHF patients. Because measurements of mitochondrial ROS generation in blood cells are less 
invasive than those in other organs, such as cardiac muscle and skeletal muscle, ROS levels in PBMC mitochon-
dria may be a useful biomarker not only for disease severity but also for the mitochondrial redox state in CHF.
The mechanism by which mitochondrial ROS generation in PBMCs was increased in CHF patients is not 
clear. One possible explanation is that an enhancement of myocardial ROS stimulates ROS generation in PBMC 
mitochondria via the mechanism of “ROS-induced ROS generation” upon the passage of circulating PBMCs 
through the heart, since it has been reported that the proportion of mitochondrial ROS-loaded blood cells is 
markedly higher in the coronary sinus than in the peripheral veins of CHF patients12. Another explanation is that 
systemic inflammation is involved—e.g., circulating cytokines could trigger ROS generation. Systemic inflam-
mation is thought to be one of the primary mechanisms of CHF pathogenesis28. Clearly, further studies will be 
needed to investigate the detailed mechanism by which oxidative stress is enhanced in the PBMC mitochondria 
of patients with CHF.
It has previously been shown that mitochondrial respiratory capacity in PBMCs is reduced in patients with 
mild left ventricular hypertrophy who have a normal left ventricular systolic function with no history of worsen-
ing HF17. Although these patients were classified as having stage A or B HF (i.e., an early stage of HF) according 
to the American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) guidelines29, 
Figure 4. Association of exercise capacity with mitochondrial ROS generation in PBMCs or with systemic 
oxidative stress in CHF patients. Associations of exercise capacity with mitochondrial ROS generation during 
each respiratory state (A–E) and of exercise capacity with systemic oxidative stress (F). Blue and red circles 
indicate CHF patients with NYHA functional class I-II (n = 15) and those with NYHA functional class III 
(n = 16), respectively. VO2, oxygen uptake. Other abbreviations are as defined in the legend to Fig. 1.
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they all had hypertension and/or type 2 diabetes17, which raises the possibility that cardiovascular risk factors 
affect the impaired mitochondrial respiratory capacity in PBMCs. In contrast, all of the CHF patients that we 
observed were classified as having either stage C or D HF according to the ACCF/AHA guidelines29, since they 
had a history of HF worsening at least once, and there was no difference in cardiovascular risk factors between the 
NYHA I-II and NYHA III groups. Accordingly, our findings of impaired mitochondrial respiratory capacity and 
increased mitochondrial ROS generation in PBMCs in CHF patients with NYHA functional class III may help 
elucidate the underlying mechanism of CHF progression rather than the pathogenesis of CHF, since the latter is 
little influenced by cardiovascular risk factors.
There are some limitations in this study. First, this is not a longitudinal study; therefore, we could not inves-
tigate whether ROS levels in PBMC mitochondria have prognostic value for CHF. Second, we could not identify 
the causality of the relationships among mitochondrial ROS levels of PBMCs, disease severity, and exercise intol-
erance in CHF patients. Third, other factors may also influence the results of PBMC mitochondrial function, 
because some medications such as statins and metformin alter the redox state. Fourth, we did not normalize 
mitochondrial ROS generation and mitochondrial respiratory capacity to mitochondrial content, and thus we 
cannot clearly identify whether PBMC mitochondrial dysfunction in patients with advanced CHF is attributable 
to intrinsic impairment of mitochondrial function or altered mitochondrial content. Finally, we did not evaluate 
the ROS levels of PBMC mitochondria in healthy subjects, and thus we could not examine whether patients with 
mild CHF already had enhanced ROS generation in their PBMC mitochondria. Since this is the first study to 
investigate the role of ROS in PBMC mitochondria in CHF, the present findings might be considered preliminary; 
they await confirmation in larger cohorts with more statistical power.
In summary, CHF patients with NYHA class III had higher levels of mitochondrial ROS in circulating PBMCs 
than those with NYHA class I-II, and the increased levels of mitochondrial ROS in PBMCs were associated with 
disease severity and exercise intolerance. Our findings provide new insights into the role of PBMC mitochondrial 
oxidative stress in the development of CHF.
Methods
Study patients. A total of 31 Japanese patients who met the Framingham Criteria and had a history of hos-
pitalization due to HF worsening were enrolled in this study. CHF patients were recruited when they presented 
at the outpatient ward for a regular visit or when they were hospitalized at Hokkaido University Hospital. All 
the patients were stable in the compensated phase of HF. CHF patients were grouped as having either mild CHF, 
defined as NYHA functional class I-II (n = 15), or moderate-to-severe CHF, defined as NYHA functional class 
III (n = 16). Patients with chronic inflammatory disease, cancer, or chronic kidney disease with current hemodi-
alysis were excluded. Written informed consent was obtained from each patient before participation in the study. 
This study was approved by the ethical committee of Hokkaido University Hospital and was registered in the 
UMIN Clinical Trials Registry: UMIN000022564. All investigations conformed to the principles outlined in the 
Declaration of Helsinki.
Study protocol. Peripheral venous blood and urine samples were collected from all subjects after a 10-h 
overnight fast. To isolate PBMCs, a Ficoll-Paque gradient medium (GE Healthcare Life Sciences, Piscataway, 
NJ) was used according to the manufacturer’s protocol for analysis of mitochondrial respiratory capacity and 
mitochondrial ROS generation in PBMCs on the same day. Portions of each obtained blood sample and urine 
sample were stored at −80 °C for later analysis of systemic oxidative stress. Plasma levels of BNP were determined 
by routine in-house analyses. Cardiac function of CHF patients was evaluated by echocardiography. The LVEF 
was measured from apical 4- and 2-chamber images using the biplane method of disks. To assess peak VO2, CHF 
patients underwent symptom-limited cardiopulmonary exercise testing using an upright bicycle ergometer with 
a ramp protocol, and respiratory gas analysis was simultaneously performed with a breath-by-breath apparatus 
(Aeromonitor AE-310S; Minato Medical Science, Osaka, Japan).
Mitochondrial respiratory capacity. The mitochondrial respiratory capacity was measured with a 
high-resolution respirometer (Oxygraph-2k; Oroboros Instruments, Innsbruck, Austria) at 37 °C within 6 h after 
blood collection, according to a previously described method with minor modifications17.
Isolated PBMCs were suspended in mitochondrial respiration medium (MiR05) containing 0.5 mM eth-
ylene glycol tetraacetic acid (Sigma-Aldrich, St. Louis, MO), 3 mM MgCl2 (Sigma-Aldrich), 20 mM taurine 
(Sigma-Aldrich), 10 mM KH2PO4 (Merck Millipore, Darmstadt, Germany), 20 mM HEPES (Sigma-Aldrich), 
110 mM D-sucrose (Carl-Roth, Karlsruhe, Germany), 60 mM K-lactobionic acid (Sigma-Aldrich), and 1 g/L 
essentially fatty acid-free bovine serum albumin (Sigma-Aldrich), and were prepared to a final cell density of 
2 × 106 cells per milliliter.
After the addition of PBMC suspension to the chamber of the respirometer, digitonin (2 μmol/L) was added to 
permeabilize the PBMCs, and the multiple substrate-uncoupler-inhibitor-titration (SUIT) protocol was applied 
to evaluate the mitochondrial respiratory capacity during each state. The respiration of CI_L (i.e., respiration 
during the leak state or state 2 with complex I-linked substrates) was measured after adding malate (final con-
centration, 2 mmol/L), pyruvate (5 mmol/L) and glutamate (10 mmol/L). Then, adenosine diphosphate (ADP; 
5 mmol/L) was added to measure the respiration of CI_P (i.e., ADP-stimulated respiration or respiration during 
state 3 with complex I-linked substrates). Succinate (a complex II-linked substrate) was added with a titration 
protocol (10 mmol/L increment) until reaching maximal respiration to measure CI + II_P (i.e., ADP-stimulated 
respiration or respiration during state 3 with complex I + II-linked substrates). CI + II_E (maximal capacity of 
ETS with complex I + II-linked substrates) was evaluated after titration of FCCP (an uncoupler, 0.5 µmol/L incre-
ments), and CII_E (maximal capacity of ETS with complex II-linked substrates) was evaluated after inhibition of 
complex I with rotenone (0.5 μmol/L).
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The respiratory rate (i.e., the O2 consumption rate or O2 flux) values are expressed as pmol/s/million cells of 
PBMCs. DatLab software (Oroboros Instruments) was used for data acquisition and data analysis.
Mitochondrial RoS generation. We measured mitochondrial ROS generation simultaneously with the 
mitochondrial respiratory capacity in the permeabilized PBMCs using a spectrofluorometer (Fluorescence 
LED2-Module; Oroboros Instruments) equipped with a respirometer, as previously described30. Mitochondrial 
ROS were evaluated after the conversion of mitochondrial superoxide (O2−) into hydrogen peroxide (H2O2) 
by the addition of superoxide dismutase (SOD). Before the permeabilization of PBMCs, we added SOD (5 U/
mL), horseradish peroxidase (1 U/mL), and Amplex® UltraRed reagent (10 µmol/L; Thermo Fisher Scientific, 
Waltham, MA) to the chamber of the respirometer. H2O2 reacts with Amplex UltraRed in a 1:1 stoichiometry 
catalyzed by horseradish peroxidase, which yields the fluorescent compound resorufin. The excitation wavelength 
was 525 nm, and fluorescence detection was at 587 nm. The fluorescence of resorufin was continuously monitored 
during the SUIT protocols (along with the measurements of mitochondrial respiratory capacity).
The H2O2 generation rate was calibrated by the titration of H2O2 in 0.1 µmol/L increments before and after 
each substrate addition, in order to eliminate the possible interference of substrates. The H2O2 generation rate is 
expressed as pmol/s/million cells of PBMCs.
Systemic oxidative stress. To assess systemic oxidative stress, we measured urinary 8-OHdG, a biomarker 
of oxidative DNA damage, with an enzyme-linked immunosorbent assay kit (Highly sensitive 8-OHdG check; 
Japan Institute for the Control of Aging, Shizuoka, Japan). The values were normalized to the urinary level of 
creatine.
Statistical analysis. Data are expressed as means ± standard deviations (SDs). We used Student’s t-tests 
for continuous variables and chi-square tests for categorical variables to compare the data between two groups. 
We conducted a Pearson’s correlation analysis to determine linear relationships between continuous variables. 
Statistical analyses were performed using GraphPad Prism 7.0a software (GraphPad Software, San Diego, CA), 
and significance was defined as P < 0.05.
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